Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: B02BD02

Adynovi(rurioctocog alfa pegol)

Hemophilia A

Marketing Authorisation Holder: Baxalta Innovations GmbH

EMA Authorisation: 08/01/2018

INN: rurioctocog alfa pegol

Indication

Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Adynovi — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.